MET and non-small cell lung carcinoma: Furthermore, in addition to the use of EGFR-TKIs, it was reported that amivantamab, which acts as a bispecific anti-EGFR and anti-MET inhibitor, showed anticancer activity in a preclinical model of EGFR-mutant NSCLC cells with EGFR-TKIs resistance.